Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus FAYOSIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus FAYOSIM.
CLARINEX D 24 HOUR vs FAYOSIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. Loratadine is a long-acting antihistamine that selectively antagonizes peripheral H1-receptors.
FAYOSIM (plecanatide) is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the luminal surface of intestinal epithelial cells, activating the receptor and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, enhancing fluid secretion and accelerating gastrointestinal transit, thereby promoting bowel movements.
1 tablet (5 mg desloratadine/120 mg pseudoephedrine) orally once daily
10 mg orally once daily
None Documented
None Documented
Desloratadine: terminal t1/2 27 hours (range 20-50h) supporting once-daily dosing. Pseudoephedrine: t1/2 5-8 hours (up to 16h in alkaline urine).
12-16 hours in healthy adults; prolonged to 20-30 hours in moderate renal impairment (CrCl <50 mL/min) requiring dose adjustment.
Desloratadine: ~87% excreted as metabolites (41% urine, 43% feces), <2% unchanged. Pseudoephedrine: ~70-90% excreted unchanged in urine.
Primarily renal elimination, 80% unchanged drug in urine; 15% biliary/fecal; 5% metabolized.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine